About this episode

Dr Andree Bates interviews Simon Arkell about the impact of AI Site Twins on clinical trial site selection and the shift towards data-driven decision making.

Clinical trial site selection is one of the biggest hidden bottlenecks in drug development, and it’s still often driven by legacy relationships, spreadsheets, and habit. In this episode, Dr Andree Bates interviews Simon Arkell , founder of Ryght, Inc , about “AI Site Twins” and why the next era of site selection shifts from institutional memory to predictive, real-time analytics. Simon explains why the current model produces terrible outcomes at scale: too many activated sites under-enrol, competition at sites is poorly understood, and sponsors often don’t see the failure until timelines have already slipped. He argues this is primarily a site selection problem, because “the easy button” of re-using familiar sites reduces data-driven decision making, even as trials get more complex and patient competition intensifies. Ryght’s approach is to build AI-powered digital replicas of research sites, creating a unique identifier and a dynamic “twin” profile that continuously improves as new data arrives. Simon walks through how protocols can be matched to sites across countries, then enriched using harmonised public data, competitive trial context, and automated outreach that…

Explore listener stats, chart rankings, contacts and more on the AI For Pharma Growth podcast page.